Circulation: Heart Failure

OCTOBER 23, 2023

Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations. Patients with HFpEF have similarly high mortality rates to patients with heart failure with reduced ejection fraction.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Quality of Life Circulation 40

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 2.7,13.4), 4.6 (-0.6,9.9)

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

Journal of the American Heart Association

DECEMBER 29, 2023

BackgroundHeart failure with preserved ejection fraction ≥50% is prevalent with few evidence‐based therapies. These changes were paralleled by improvements in heart failure‐related quality of life (myPACE Minnesota Living with Heart Failure Questionnaire improved by 16.1 points, whereas usual care worsened by 6.9

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Quality of Life Echocardiogram 40

Med Page Today

NOVEMBER 18, 2024

(MedPage Today) -- CHICAGO -- The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF), the phase II ENDEAVOR.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Quality of Life Heart Failure 52

Circulation

NOVEMBER 17, 2024

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. Circulation, Ahead of Print. The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).Conclusions:

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Overall, 60.9% of patients had BMI ≥30 kg/m 2.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

European Journal of Heart Failure

NOVEMBER 29, 2023

Methods Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries.

Heart Failure 75

Heart Failure Preserved Ejection Fraction Quality of Life Biomarkers 75

Circulation

SEPTEMBER 2, 2024

Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Quality of Life Article Heart Failure 45

The American Journal of Cardiology

APRIL 15, 2024

Publication date: Available online 13 April 2024 Source: The American Journal of Cardiology Author(s): Syed Imran Ahmed, Jonathan Kenyon, Hayley E. Billingsley, Hannah Salmons, Natalie J. Bohmke, Roshanak Markley, Antonio Abbate, Danielle L. Kirkman, Youngdeok Kim, Salvatore Carbone

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Heart Failure 40

Circulation: Heart Failure

DECEMBER 6, 2024

BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life. In heart failure with reduced ejection fraction, exercise stimulates a reflex increase in muscle sympathetic nerve activity (MSNA) that relates inversely to peak oxygen uptake (VO2peak).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Exercise Heart Failure Quality of Life 40

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 75

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 75

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

Patients diagnosed with reduced ejection fraction (HFrEF) and with heart failure with mildly reduced ejection fraction (HFmrEF) were treated with Vericiguat combined with “ARNI, BB, MRA, SGLT2i” therapy. and improved patients’ quality of life scores. vs. 43.1 ± 8.5%, P < 0.01), LVEDD (60.5 ± 8.1

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

European Journal of Heart Failure

DECEMBER 20, 2023

Abstract Introduction Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF).

Quality of Life 40

Quality of Life Preserved Ejection Fraction Pacemaker Heart Failure 40

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

Heart BMJ

FEBRUARY 12, 2024

To be familiar with the specific considerations of exercise training prescription in specific HF population groups including HF with preserved ejection fraction. To understand the key principles of exercise training prescription in people with HF. cross-ref type="bib".

Exercise 40

Exercise Heart Failure Preserved Ejection Fraction Pharmacology 40

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The study was funded by Imbria Pharmaceuticals, developer of ninerafaxstat.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

The British Journal of Cardiology

AUGUST 21, 2024

In the only large, randomised trial of patients with HF with reduced ejection fraction (HFrEF), digoxin demonstrated a reduction in hospitalisation with no adverse effect on total mortality but patients in AF were excluded.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Preserved Ejection Fraction Quality of Life 40

Circulation

NOVEMBER 11, 2024

The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients were divided into two groups based on BB use at trial enrollment. After controlling for potential confounding variables, there were no differences in baseline exercise capacity [peak VO2 (mL/kg/min): 12.1

Quality of Life 40

Quality of Life Preserved Ejection Fraction Exercise Heart Failure 40

DAIC

MARCH 29, 2024

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. HFpEF is HF with preserved ejection fraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111

Cardiometabolic Health Congress

NOVEMBER 14, 2024

What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. cardiometabolic health CME/CE conference: the 19th Annual CMHC.

CME 103

CME Obesity Heart Failure Biomarkers 103

Frontiers in Cardiovascular Medicine

NOVEMBER 10, 2024

BackgroundHeart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) often coincide. Female sex is associated with both increased prevalence of HFpEF and reduced therapeutic efficacy of catheter ablation of AF. Forty-two were female. ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2,

Preserved Ejection Fraction 52

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 52